Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
 

Corporate Investor Presentation

Rigel Corporate Investor Presentation

More »
Recent News
DateTitle 
11/15/19
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
SOUTH SAN FRANCISCO, Calif. , Nov. 15, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency , has adopted a positive opinion for Rigel's Marketing
11/13/19
Rigel to Present at Jefferies 2019 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21,
11/07/19
Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition
78% response rate in ITP patients who received fostamatinib as second-line therapy in post-hoc analysis SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)
Volume
Data as of
More »
Upcoming Events
More events are coming soon.

Stock Chart

Copyright West LLC. Minimum 15 minutes delayed.

What's New

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site